首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | INGAP |
| Uniprot No | Q06141 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 27-175aa |
| 氨基酸序列 | EEPQRELPSARIRCPKGSKAYGSHCYALFLSPKSWTDADLACQKRPSGNLVSVLSGAEGSFVSSLVKSIGNSYSYVWIGLHDPTQGTEPNGEGWEWSSSDVMNYFAWERNPSTISSPGHCASLSRSTAFLRWKDYNCNVRLPYVCKFTD |
| 预测分子量 | 43.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于INGAP重组蛋白的模拟参考文献示例(注：内容为示例，建议通过学术数据库核实准确性)：
---
1. **文献名称**：*INGAP-Pentadecapeptide Enhances β-Cell Regeneration and Glucose Homeostasis in Rodents*
**作者**：Rafael A. Vega, Laura I. Sánchez-Soto
**摘要**：研究报道INGAP重组多肽(INGAP-PP)通过激活胰腺导管细胞分化，促进β细胞再生，改善链脲佐菌素(STZ)诱导的糖尿病小鼠血糖控制。
2. **文献名称**：*Recombinant INGAP Protein Stimulates Islet Neogenesis in a Diabetic Rat Model*
**作者**：G.L. Pittenger, A. Taylor-Fishwick
**摘要**：在糖尿病大鼠模型中，INGAP重组蛋白通过上调胰腺再生相关基因(如PDX-1)，诱导胰岛新生，显著提升胰岛素分泌能力。
3. **文献名称**：*Phase II Clinical Trial of INGAP Peptide in Type 1 Diabetes: Safety and Metabolic Effects*
**作者**：L. Rosenberg, K.L. Lipsett
**摘要**：二期临床试验评估INGAP重组多肽的安全性，结果显示其对1型糖尿病患者C肽水平有轻微提升，但未达主要疗效终点。
4. **文献名称**：*Mechanistic Insights into INGAP-Mediated Islet Cell Proliferation*
**作者**：M.J. Taylor, D.R. Layton
**摘要**：体外实验表明，INGAP重组蛋白通过激活ERK1/2和PI3K/Akt信号通路，促进人胰岛细胞增殖并抑制凋亡。
---
**说明**：以上为基于领域知识的模拟文献，实际研究请通过PubMed、Web of Science等平台检索关键词“INGAP recombinant protein”或“INGAP-PP”获取。部分早期研究集中于2000-2010年间，近年可能涉及递送系统优化(如纳米载体)或联合疗法探索。
INGAP (Islet Neogenesis-Associated Protein) is a pancreatic protein first identified in the 1990s during studies on pancreatic regeneration. It belongs to the Reg family of proteins, which are associated with cell proliferation, differentiation, and tissue repair. INGAP gained attention for its potential role in stimulating the growth of pancreatic islet cells, particularly insulin-producing β-cells, which are critical in diabetes management.
The protein is encoded by the *REG3A* gene and consists of 175 amino acids, including a signal peptide and a conserved C-type lectin domain. Its expression is upregulated during pancreatic injury or metabolic stress, suggesting a natural regenerative response. Preclinical studies in animal models demonstrated that INGAP promotes islet neogenesis—the formation of new insulin-secreting cells—and enhances β-cell mass, improving glucose regulation in diabetic rodents.
Researchers developed recombinant INGAP (rINGAP) using biotechnological methods, such as bacterial or mammalian expression systems, to produce the protein in bulk for therapeutic exploration. The recombinant form retains bioactivity, enabling studies on its mechanisms and therapeutic potential. Early-phase clinical trials in type 1 and type 2 diabetes patients explored INGAP-derived peptides, showing modest improvements in β-cell function and glucose control, though results were inconsistent.
The exact molecular mechanism remains unclear, but INGAP is thought to interact with cell surface receptors, activating pathways like MAPK/ERK or PI3K/Akt to drive β-cell proliferation and survival. Challenges include optimizing delivery methods and understanding its pleiotropic effects on other tissues.
Overall, INGAP represents a promising but experimental approach for diabetes treatment, focusing on restoring endogenous insulin production rather than external supplementation. Further research aims to refine its therapeutic efficacy and safety profile.
×
